INSM vs the Top Picks average
| Pillar | INSM | Book avg | Diff |
|---|---|---|---|
| Quality | 0.11 | 0.84 | -0.73 |
| Growth | 0.98 | 0.84 | +0.14 |
| Value | 0.55 | 0.78 | -0.23 |
Averaged across the 30 names in today's Top Picks (mean score 81.5). A name can beat these averages and still be absent from the book — it also applies concentration limits.
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Analyst estimate revisions
| 30-day change | -15.5% |
|---|---|
| 90-day change | -15.5% |
| Forward EPS estimate | $0.72 |
Over the last 90 days, what analysts expect INSM to earn is materially lower (-15.5%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
A rising estimate means expectations are improving, not that the price has failed to keep up — and estimates get cut as readily as they get raised. It is not part of the Bull Rankings score. Biggest movers across the market →
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Insmed Incorporated (INSM): score, valuation & FAQ
Insmed Incorporated (INSM) is a Biotechnology company that scores 38.6 out of 100 on the Bull Rankings quality-growth model — a below-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A) and PEG (B+), while P/S (D) and FCF (F) rate weaker.
Is INSM a good stock to buy?
Bull Rankings scores INSM 38.6 out of 100 on its quality-growth model, which is a below-average reading. That is driven by Rev (A) and PEG (B+). A score is a quantitative screen of Insmed Incorporated's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does INSM score 38.6 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). INSM earns its highest marks on Rev (A) and PEG (B+), and is held back by P/S (D) and FCF (F). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is INSM overvalued or undervalued?
We don't compute a reliable discounted-cash-flow value for INSM — typically because it is not yet consistently profitable or free-cash-flow positive — so its valuation rests on growth and price-to-sales rather than on earnings-based intrinsic value. Judge it on the trajectory of the business, not a single multiple.
What are the main risks of investing in INSM?
Free cash flow is negative (-$808m) — capital raises or debt issuance likely required; dilution / leverage risk. Currently unprofitable (margin -76.9%) — path to GAAP profitability is the core thesis risk. Down 41% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial advisor.